Evolutionary Tree Capital Management LLC Sells 34,041 Shares of PROCEPT BioRobotics Corporation $PRCT

Evolutionary Tree Capital Management LLC lowered its stake in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) by 33.7% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 66,869 shares of the company’s stock after selling 34,041 shares during the period. PROCEPT BioRobotics makes up approximately 3.1% of Evolutionary Tree Capital Management LLC’s portfolio, making the stock its 16th biggest holding. Evolutionary Tree Capital Management LLC owned about 0.12% of PROCEPT BioRobotics worth $1,672,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its holdings in shares of PROCEPT BioRobotics by 142.0% in the fourth quarter. SG Americas Securities LLC now owns 84,294 shares of the company’s stock valued at $2,652,000 after purchasing an additional 49,457 shares in the last quarter. Baillie Gifford & Co. boosted its position in shares of PROCEPT BioRobotics by 18.3% during the fourth quarter. Baillie Gifford & Co. now owns 1,015,978 shares of the company’s stock valued at $31,963,000 after buying an additional 157,147 shares during the last quarter. B. Metzler seel. Sohn & Co. AG bought a new stake in PROCEPT BioRobotics during the fourth quarter worth $1,864,000. Pinnacle Associates Ltd. bought a new stake in PROCEPT BioRobotics during the fourth quarter worth $3,876,000. Finally, DNB Asset Management AS raised its position in PROCEPT BioRobotics by 213.9% in the 4th quarter. DNB Asset Management AS now owns 99,567 shares of the company’s stock valued at $3,132,000 after buying an additional 67,848 shares during the last quarter. 89.46% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Citigroup cut PROCEPT BioRobotics to a “hold” rating in a research note on Thursday, July 2nd. Piper Sandler reiterated an “overweight” rating and issued a $35.00 target price (up from $28.00) on shares of PROCEPT BioRobotics in a research note on Thursday, April 30th. Leerink Partners downgraded shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $31.00 to $29.00 in a report on Thursday, June 11th. Wall Street Zen raised shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, Truist Financial restated a “hold” rating and set a $25.00 price target (down from $30.00) on shares of PROCEPT BioRobotics in a report on Thursday, July 2nd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $33.45.

PROCEPT BioRobotics Stock Performance

Shares of PRCT opened at $18.62 on Friday. The company has a current ratio of 6.73, a quick ratio of 5.51 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -10.23 and a beta of 0.87. The stock has a 50 day moving average of $22.39 and a 200 day moving average of $25.19. PROCEPT BioRobotics Corporation has a 12 month low of $16.67 and a 12 month high of $51.38.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its quarterly earnings results on Wednesday, April 29th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.01). PROCEPT BioRobotics had a negative return on equity of 27.70% and a negative net margin of 31.82%.The business had revenue of $83.13 million for the quarter, compared to the consensus estimate of $80.52 million. During the same quarter last year, the business posted ($0.45) earnings per share. The business’s revenue was up 20.1% compared to the same quarter last year. As a group, sell-side analysts forecast that PROCEPT BioRobotics Corporation will post -1.53 earnings per share for the current year.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek appointment as lead plaintiff in the pending class action. The notices are procedural and do not represent a court finding of wrongdoing. Deadline Alert: Procept BioRobotics Corporation Shareholders
• Negative Sentiment: The core allegations involve repeated underperformance in unit and handpiece sales, late-quarter bulk discounts, excess customer inventory, and sales being pulled forward. Plaintiffs allege these practices may have inflated recurring-revenue metrics and that the risks were not adequately disclosed. PROCEPT Faces Securities Class Action Amid Sales Pull-In Concerns
• Negative Sentiment: The unusually high volume of nearly identical law-firm announcements increases the visibility of the litigation and could weigh on the stock through potential legal costs, reputational damage, and uncertainty regarding the sustainability of demand and future revenue growth. PROCEPT Securities Fraud Class Action and Inventory Issues
• Negative Sentiment: UBS reportedly lowered its rating on PRCT to “Neutral,” adding to the cautious backdrop surrounding the company and its sales outlook. PROCEPT Rating Lowered to Neutral at UBS

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.